Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groupsMarie Robin, Jean‐Jacques Kiladjian, David Michonneau et al.|Bone Marrow Transplantation|2021Cited by 32
Suggestive evidence of a role of HLA-DRB4 mismatches in the outcome of allogeneic hematopoietic stem cell transplantation with HLA-10/10-matched unrelated donors: a French–Swiss retrospective studyMarie Y. Detrait, Valérie Dubois, Stéphane Morisset et al.|Bone Marrow Transplantation|2015Cited by 21
Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Marie Y. Detrait, Mauricette Michallet, Stéphane Morisset et al.|Bone Marrow Transplantation|2014Cited by 8
Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french associationAdriana Pleșa, Christophe Roumier, Alexandra Coelho et al.|Blood|2025Cited by 1
Risk Factors to Develop Sclerotic Chronic GvHD After Allogeneic HSCT: Preliminary Results of a Multicentre Retrospective study From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)Marie Y. Detrait, Mauricette Michallet, Roberto Crocchiolo et al.|Blood|2012Cited by 0